Tags

Type your tag names separated by a space and hit enter

Artificial sweeteners and the risk of gastric, pancreatic, and endometrial cancers in Italy.

Abstract

BACKGROUND

The role of sweeteners on cancer risk has been widely debated over the last few decades. To provide additional information on saccharin and other artificial or low-calorie sweeteners (mainly aspartame), we updated the analysis of an integrated network of case-control studies conducted in Italy between 1991 and 2004 including data on cancers of the stomach, pancreas, and endometrium.

PATIENTS AND METHODS

Cases were 230 patients with incident, histologically confirmed cancers of the stomach and 547 corresponding controls, 326 of the pancreas and 652 controls, and 454 of the endometrium and 908 controls. All controls were patients admitted to the same hospitals as cases for acute, non-neoplastic disorders. Odds ratios (OR) and corresponding confidence intervals (CI) were derived by unconditional logistic regression models.

RESULTS

After allowance for various confounding factors, ORs for ever users of sweeteners versus nonusers were 0.80 (95% CI, 0.45-1.43) for gastric cancer, 0.62 (95% CI, 0.37-1.04) for pancreatic cancer, and 0.96 (95% CI, 0.67-1.40) for endometrial cancer. Corresponding ORs for saccharin were 0.65, 0.19, and 0.71, and for other sweeteners were 0.86, 1.16, and 1.07, respectively, for the three cancer sites.

CONCLUSIONS

The present study adds further evidence on the absence of an adverse effect of low-calorie sweetener (including aspartame) consumption on the risk of common neoplams in the Italian population.

Authors+Show Affiliations

Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. bosetti@marionegri.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19661082

Citation

Bosetti, Cristina, et al. "Artificial Sweeteners and the Risk of Gastric, Pancreatic, and Endometrial Cancers in Italy." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 18, no. 8, 2009, pp. 2235-8.
Bosetti C, Gallus S, Talamini R, et al. Artificial sweeteners and the risk of gastric, pancreatic, and endometrial cancers in Italy. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2235-8.
Bosetti, C., Gallus, S., Talamini, R., Montella, M., Franceschi, S., Negri, E., & La Vecchia, C. (2009). Artificial sweeteners and the risk of gastric, pancreatic, and endometrial cancers in Italy. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 18(8), pp. 2235-8. doi:10.1158/1055-9965.EPI-09-0365.
Bosetti C, et al. Artificial Sweeteners and the Risk of Gastric, Pancreatic, and Endometrial Cancers in Italy. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2235-8. PubMed PMID: 19661082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Artificial sweeteners and the risk of gastric, pancreatic, and endometrial cancers in Italy. AU - Bosetti,Cristina, AU - Gallus,Silvano, AU - Talamini,Renato, AU - Montella,Maurizio, AU - Franceschi,Silvia, AU - Negri,Eva, AU - La Vecchia,Carlo, PY - 2009/8/8/entrez PY - 2009/8/8/pubmed PY - 2009/10/21/medline SP - 2235 EP - 8 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 18 IS - 8 N2 - BACKGROUND: The role of sweeteners on cancer risk has been widely debated over the last few decades. To provide additional information on saccharin and other artificial or low-calorie sweeteners (mainly aspartame), we updated the analysis of an integrated network of case-control studies conducted in Italy between 1991 and 2004 including data on cancers of the stomach, pancreas, and endometrium. PATIENTS AND METHODS: Cases were 230 patients with incident, histologically confirmed cancers of the stomach and 547 corresponding controls, 326 of the pancreas and 652 controls, and 454 of the endometrium and 908 controls. All controls were patients admitted to the same hospitals as cases for acute, non-neoplastic disorders. Odds ratios (OR) and corresponding confidence intervals (CI) were derived by unconditional logistic regression models. RESULTS: After allowance for various confounding factors, ORs for ever users of sweeteners versus nonusers were 0.80 (95% CI, 0.45-1.43) for gastric cancer, 0.62 (95% CI, 0.37-1.04) for pancreatic cancer, and 0.96 (95% CI, 0.67-1.40) for endometrial cancer. Corresponding ORs for saccharin were 0.65, 0.19, and 0.71, and for other sweeteners were 0.86, 1.16, and 1.07, respectively, for the three cancer sites. CONCLUSIONS: The present study adds further evidence on the absence of an adverse effect of low-calorie sweetener (including aspartame) consumption on the risk of common neoplams in the Italian population. SN - 1538-7755 UR - https://www.unboundmedicine.com/medline/citation/19661082/Artificial_sweeteners_and_the_risk_of_gastric_pancreatic_and_endometrial_cancers_in_Italy_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=19661082 DB - PRIME DP - Unbound Medicine ER -